IMAGEN MOLECULAR PET-TC EN EL CANCER DE MAMA

Autores/as

  • Antonio Maldonado Suarez
  • Vicente Martinez De Vega
  • Susana Linares Gonzalez
  • Silvia Fuertes Cabero
  • Gines Hernandez Cortes
  • Javier Hornedo Muguiro

Palabras clave:

CANCER DE MAMA, PET-TC, POSTER, SERAM

Resumen

Objetivos Docentes
Describir el rendimiento diagnóstico de la prueba en las diferentes situaciones clínicas donde tiene utilidad
Exponer los nuevos avances tanto en instrumentación como en radiofármacos. Explicar la importancia como factor pronóstico de supervivencia y predictor de la respuesta al tratamiento

Revisión del tema
El cáncer de mama es el de mayor prevalencia en mujeres, con una tasa de mortalidad en España de 26,7 de cada 100.000, siendo la principal causa de muerte en las mujeres de entre 40−55 años. La supervivencia a los 5 años varía entre el 98% en las pacientes con enfermedad localizada, el 83% en las pacientes con enfermedad regional y el 27% en las pacientes con enfermedad diseminada, existiendo recidiva de forma general entre un 20−35% de las pacientes, ya sea locorregional o a distancia, en los 10 primeros años

Descargas

Los datos de descargas todavía no están disponibles.

Citas

ROLE OF POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN BREAST CANCER. Bourgeois AC, Warren LA, Chang TT, Embry S, Hudson K, Bradley YC. Radiol Clin North Am. 2013 Sep;51(5):781-98.

F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, Guiu S, Coutant C, Coudert B, Fumoleau P, Brunotte F. Eur J Nucl Med Mol Imaging. 2013 Nov

F-FDG UPTAKE IN BREAST CANCER CORRELATES WITH IMMUNOHISTOCHEMICALLY DEFINED SUBTYPES Hye Ryoung Koo, European Radiology October 2013

Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study. Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, Okada M. Breast Cancer Res Treat. 2013 Sep;141(2):269-75.

CORRELATION OF 18F-FLUORODEOXYGLUCOSE UPTAKE WITH HISTOPATHOLOGICAL PROGNOSTIC FACTORS IN BREAST CARCINOMA. Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, Kaya R, Kocael P, Erkan ME, Halac M, Sonmezoglu K. Nucl Med Commun. 2013 Nov;34(11):1055-67

MOLECULAR SUBTYPES OF BREAST CANCER: METABOLIC CORRELATION WITH 18F-FDG PET/CT. García Vicente AM, Soriano Castrejón A, León Martín A, Chacón López-Muñiz I, Muñoz Madero V, Muñoz Sánchez MD, Palomar Muñoz A, Espinosa Aunión R,González Ageitos A. Eur J Nucl Med Mol Imaging. 2013 Apr 30

A NEW METHOD FOR APPARENT DIFFUSION COEFFICIENT MEASUREMENT USING SEQUENTIAL18F-FDG PET AND MRI: CORRELATION WITH HISTOLOGICAL GRADE OF INVASIVE DUCTAL CARCINOMA OF THE BREAST Annals of Nuclear Medicine October 2013, Volume 27, Issue 8, pp 720-728 Byung Hyun Byun,

BREAST CANCER DETECTION USING HIGH-RESOLUTION BREAST PET COMPARED TO WHOLE-BODY PET OR PET/CT. Kalinyak JE, Berg WA, Schilling K, Madsen KS, Narayanan D, Tartar M.

Eur J Nucl Med Mol Imaging. 2013 Oct 2

DETECTION OF INTERNAL MAMMARY LYMPH NODE METASTASIS WITH 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN PATIENTS WITH STAGE III BREAST CANCER. Seo MJ, Lee JJ, Kim HO, Chae SY, Park SH, Ryu JS, Ahn SH, Lee JW, Son BH, Gong GY, Moon DH. Eur J Nucl Med Mol Imaging. 2013 Nov 6.

F-FDG PET/CT–POSITIVE INTERNAL MAMMARY LYMPH NODES: PATHOLOGIC CORRELATION BY ULTRASOUND-GUIDED FINE-NEEDLE ASPIRATION AND ASSESSMENT OF ASSOCIATED RISK FACTORS Carolyn L. Wang1, 2, Marna J. Eissa2, 3, James V. Rogers1, Aleksandr Y. Aravkin2, 4, Bruce A. Porter1and J. David Beatty1 American Journal of Roentgenology, Vol. 200, No. 5, May: 1138-1144

DIAGNOSTIC PERFORMANCE OF 18F-FDG PET/CT, ULTRASONOGRAPHY AND MRI. DETECTION OF AXILLARY LYMPH NODE METASTASIS IN BREAST CANCER PATIENTS. An YS, Lee DH, Yoon JK, Lee SJ, Kim TH, Kang DK, Kim KS, Jung YS, Yim H. Nuklearmedizin. 2013 Nov 13;53(1).

LYMPH NODE TO PRIMARY TUMOR SUV RATIO BY 18F-FDG PET/CT AND THE PREDICTION OF AXILLARY LYMPH NODE METASTASES IN BREAST CANCER. Park J, Byun BH, Noh WC, Lee SS, Kim HA, Kim EK, Choi CW, Lim SM. Clin Nucl Med. 2013 Oct 22

THE COMPARATIVE STUDY OF ULTRASONOGRAPHY, CONTRAST-ENHANCED MRI, AND (18)F-FDG PET/CT FOR DETECTING AXILLARY LYMPH NODE METASTASIS IN T1 BREAST CANCER.

Hwang SO, Lee SW, Kim HJ, Kim WW, Park HY, Jung JH. J Breast Cancer. 2013 Sep;16(3):315-21

DUAL TIME POINT 2-DEOXY-2-[(18)F]FLUORO-D-GLUCOSE PET/CT: NODAL STAGING IN LOCALLY ADVANCED BREAST CANCER. García Vicente AM,et al Rev Esp Med Nucl Imagen Mol. 2013 May 23.

THE CLINICAL VALUE OF TUMOR FDG UPTAKE FOR PREDICTING AXILLARY LYMPH NODE METASTASIS IN BREAST CANCER WITH CLINICALLY NEGATIVE AXILLARY LYMPH NODES. Seok JW, Kim Y, An YS, Kim BS. Ann Nucl Med. 2013 Jul;27(6):546-53

ROLE OF 18F-FDG PET/CT IN IDENTIFYING DISTANT METASTATIC DISEASE MISSED BY CONVENTIONAL IMAGING IN PATIENTS WITH LOCALLY ADVANCED BREAST CANCER. Manohar K, Mittal BR, Bhoil A, Bhattacharya A, Singh G. Nucl Med Commun. 2013 Jun;34(6):557-61

FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. Hong S, Li J, Wang S. Surg Oncol. 2013 Apr 5.

THE IMPACT OF PET/CT IMAGING PERFORMED IN THE EARLY POSTOPERATIVE PERIOD ON THE MANAGEMENT OF BREAST CANCER PATIENTS. Sen F, Akpinar AT, Ogur U, Duman G, amgac F, Alper E. Nucl Med Commun. 2013 Jun;34(6):571-6

F-FDG PET/CT PREDICTS SURVIVAL IN PATIENTS WITH INFLAMMATORY BREAST CANCER UNDERGOING NEOADJUVANT CHEMOTHERAPY Selin Carkaci , Christopher T. Sherman , Efe Ozkan , Beatriz E. Adrada , Wei Wei , Eric M. Rohren , Osama R. Mawlawi , Naoto T. Ueno , Thomas A. Buchholz & Wei T. Yang Eur J Nucl Med Mol Imaging (2013) 40:1809–1816

F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO. J Nucl Med. 2013 Nov;54(11):1862-8. Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, Van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P,Cure H, Eidtmann H, Baselga J, Piccart M, Flamen P, Di Cosimo S.

CAN FDG-PET/CT PREDICT EARLY RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER? Andrade WP, Lima EN, Osório CA, do Socorro Maciel M, Baiocchi G, Bitencourt AG, Fanelli MF, Damascena AS, Soares FA. Eur J Surg Oncol. 2013 Oct 2. pii: S0748-7983(13)

F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: association of loco regional suvmax with classical prognostic factors. García García-Esquinas M, García-Sáenz JA, Arrazola García J, Enrique Fuentes Ferrer M, Furió V, Rodriguez Rey C, Román JM, Carreras Delgado JL. Q J Nucl Med Mol Imaging. 2013 Oct 9.

PRE-CHEMOTHERAPY 18F-FDG PET/CT UPSTAGES NODAL STAGE IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY. Koolen BB, Valdés Olmos RA, Vogel WV, Vrancken Peeters MJ, Rodenhuis S, Rutgers EJ, Elkhuizen PH. Breast Cancer Res Treat. 2013 Sep 4

EARLY ASSESSMENT OF AXILLARY RESPONSE WITH 18F-FDG PET/CT DURING NEOADJUVANT CHEMOTHERAPY IN STAGE II–III BREAST CANCER: IMPLICATIONS FOR SURGICAL ANAGEMENT OF THE AXILLA Annals of Surgical Oncology July 2013, Volume 20, Issue 7, pp 2227-2235 Bas B. Koolen MD

DOES THE PRETREATMENT TUMOR SAMPLING LOCATION CORRESPOND WITH METABOLIC ACTIVITY ON 18F-FDG PET/CT IN BREAST CANCER PATIENTS SCHEDULED FOR NEOADJUVANT CHEMOTHERAPY? Koolen BB, Elshof LE, Loo CE, Wesseling J, Vrancken Peeters MJ, Vogel WV, Rutgers EJ, Valdés Olmos RA. Eur J Radiol. 2013 Aug

PET/CT WITH [18F] FLUORODEOXYGLUCOSE IN THE ASSESSMENT OF METABOLIC RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED BREAST CANCER. Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M, Skaltsa K, Domènech B, Lomeña F, Pons F. Q J Nucl Med Mol Imaging. 2012 Jun;56(3):291-8.

FLUORINE-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY IN MONITORING THE RESPONSE OF BREAST CANCER TO NEOADJUVANT CHEMOTHERAPY: A META-ANALYSIS. Mghanga FP, Lan X, Bakari KH, Li C, Zhang Y. Clin Breast Cancer. 2013 Aug;13(4):271-9.

ESTROGEN RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST TUMORS: EARLY PREDICTION OF CHEMOSENSITIVITY WITH (18)F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY DURING NEOADJUVANT CHEMOTHERAPY. Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D,Espié M.. Cancer. 2013 Jun 1;119(11):1960-8

VOLUME-BASED PARAMETERS OF 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IMPROVE DISEASE RECURRENCE PREDICTION IN POSTMASTECTOMY BREAST CANCER PATIENTS WITH 1 TO 3 POSITIVE AXILLARY LYMPH NODES International Journal of Radiation Oncology * Biology * Physics Volume 87, Issue 4 , Pages 738-746, 15 November 2013. Naomi Nakajima, MD

Descargas

Publicado

2018-11-22

Cómo citar

Maldonado Suarez, A., Martinez De Vega, V., Linares Gonzalez, S., Fuertes Cabero, S., Hernandez Cortes, G., & Hornedo Muguiro, J. (2018). IMAGEN MOLECULAR PET-TC EN EL CANCER DE MAMA. Seram. Recuperado a partir de https://piper.espacio-seram.com/index.php/seram/article/view/1622

Número

Sección

Unidad de Mama

Artículos más leídos del mismo autor/a

1 2 3 > >>